Literature DB >> 24827908

ID proteins regulate diverse aspects of cancer progression and provide novel therapeutic opportunities.

Radhika Nair1, Wee Siang Teo1, Vivek Mittal2, Alexander Swarbrick3.   

Abstract

The inhibitor of differentiation (ID) proteins are helix-loop-helix transcriptional repressors with established roles in stem cell self-renewal, lineage commitment, and niche interactions. While deregulated expression of ID proteins in cancer was identified more than a decade ago, emerging evidence has revealed a central role for ID proteins in neoplastic progression of multiple tumor types that often mirrors their function in physiological stem and progenitor cells. ID proteins are required for the maintenance of cancer stem cells, self-renewal, and proliferation in a range of malignancies. Furthermore, ID proteins promote metastatic dissemination through their role in remodeling the tumor microenvironment and by promoting tumor-associated endothelial progenitor cell proliferation and mobilization. Here, we discuss the latest findings in this area and the clinical opportunities that they provide.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24827908      PMCID: PMC4435600          DOI: 10.1038/mt.2014.83

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  144 in total

1.  Degradation of Id2 by the anaphase-promoting complex couples cell cycle exit and axonal growth.

Authors:  Anna Lasorella; Judith Stegmüller; Daniele Guardavaccaro; Guangchao Liu; Maria S Carro; Gerson Rothschild; Luis de la Torre-Ubieta; Michele Pagano; Azad Bonni; Antonio Iavarone
Journal:  Nature       Date:  2006-06-28       Impact factor: 49.962

2.  Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells.

Authors:  Laurent David; Christine Mallet; Sabine Mazerbourg; Jean-Jacques Feige; Sabine Bailly
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

3.  The expression pattern of Id4, a novel dominant negative helix-loop-helix protein, is distinct from Id1, Id2 and Id3.

Authors:  V Riechmann; I van Crüchten; F Sablitzky
Journal:  Nucleic Acids Res       Date:  1994-03-11       Impact factor: 16.971

4.  Inhibitor of DNA binding-1 induces mesenchymal features and promotes invasiveness in thyroid tumour cells.

Authors:  Alessia Ciarrocchi; Simonetta Piana; Roberto Valcavi; Giorgio Gardini; Bruno Casali
Journal:  Eur J Cancer       Date:  2010-12-09       Impact factor: 9.162

5.  Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance.

Authors:  Mariano Ponz-Sarvisé; Paul A Nguewa; María J Pajares; Jackeline Agorreta; María D Lozano; Miriam Redrado; Ruben Pio; Carmen Behrens; Ignacio I Wistuba; Carlos E García-Franco; Jesús García-Foncillas; Luis M Montuenga; Alfonso Calvo; Ignacio Gil-Bazo
Journal:  Clin Cancer Res       Date:  2011-05-03       Impact factor: 12.531

6.  Prognostic relevance of Id-1 expression in patients with resectable esophageal squamous cell carcinoma.

Authors:  Kong-Jia Luo; Jing Wen; Xuan Xie; Jian-Hua Fu; Rong-Zhen Luo; Qiu-Liang Wu; Yi Hu
Journal:  Ann Thorac Surg       Date:  2012-04-04       Impact factor: 4.330

7.  Inhibitor of differentiation 4 drives brain tumor-initiating cell genesis through cyclin E and notch signaling.

Authors:  Hye-Min Jeon; Xun Jin; Joong-Seob Lee; Se-Yeong Oh; Young-Woo Sohn; Hyo-Jung Park; Kyeung Min Joo; Woong-Yang Park; Do-Hyun Nam; Ronald A DePinho; Lynda Chin; Hyunggee Kim
Journal:  Genes Dev       Date:  2008-08-01       Impact factor: 11.361

8.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

Authors:  Roland Schmitz; Ryan M Young; Michele Ceribelli; Sameer Jhavar; Wenming Xiao; Meili Zhang; George Wright; Arthur L Shaffer; Daniel J Hodson; Eric Buras; Xuelu Liu; John Powell; Yandan Yang; Weihong Xu; Hong Zhao; Holger Kohlhammer; Andreas Rosenwald; Philip Kluin; Hans Konrad Müller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Martin D Ogwang; Steven J Reynolds; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Wing C Chan; Stefania Pittaluga; Wyndham Wilson; Thomas A Waldmann; Martin Rowe; Sam M Mbulaiteye; Alan B Rickinson; Louis M Staudt
Journal:  Nature       Date:  2012-08-12       Impact factor: 49.962

9.  Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.

Authors:  Winnie F Tam; Ting-Lei Gu; Jing Chen; Benjamin H Lee; Lars Bullinger; Stefan Fröhling; Andrew Wang; Stefano Monti; Todd R Golub; D Gary Gilliland
Journal:  Blood       Date:  2008-06-17       Impact factor: 22.113

10.  The perivascular niche regulates breast tumour dormancy.

Authors:  Cyrus M Ghajar; Héctor Peinado; Hidetoshi Mori; Irina R Matei; Kimberley J Evason; Hélène Brazier; Dena Almeida; Antonius Koller; Katherine A Hajjar; Didier Y R Stainier; Emily I Chen; David Lyden; Mina J Bissell
Journal:  Nat Cell Biol       Date:  2013-06-02       Impact factor: 28.824

View more
  23 in total

1.  Inhibitor of differentiation proteins protect against oxidative stress by regulating the antioxidant-mitochondrial response in mouse beta cells.

Authors:  Mohammed Bensellam; Magdalene K Montgomery; Jude Luzuriaga; Jeng Yie Chan; D Ross Laybutt
Journal:  Diabetologia       Date:  2015-01-31       Impact factor: 10.122

2.  Suppression of invasion and metastasis in aggressive salivary cancer cells through targeted inhibition of ID1 gene expression.

Authors:  Ryuichi Murase; Tomoki Sumida; Rumi Kawamura; Akiko Onishi-Ishikawa; Hiroyuki Hamakawa; Sean D McAllister; Pierre-Yves Desprez
Journal:  Cancer Lett       Date:  2016-04-14       Impact factor: 8.679

Review 3.  Exploring the molecular role of endostatin in diabetic neuropathy.

Authors:  Tuhin Mukherjee; Tapan Behl; Aayush Sehgal; Saurabh Bhatia; Harmanpreet Singh; Simona Bungau
Journal:  Mol Biol Rep       Date:  2021-02-09       Impact factor: 2.316

4.  Brain infiltration of breast cancer stem cells is facilitated by paracrine signaling by inhibitor of differentiation 3 to nuclear respiratory factor 1.

Authors:  Jayanta K Das; Alok Deoraj; Deodutta Roy; Quentin Felty
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-09       Impact factor: 4.322

5.  HSP70 inhibition blocks adaptive resistance and synergizes with MEK inhibition for the treatment of NRAS-mutant melanoma.

Authors:  Joshua L D Parris; Thibaut Barnoud; Julia I-Ju Leu; Jessica C Leung; Weili Ma; Nicole A Kirven; Adi Naryana Reddy Poli; Andrew V Kossenkov; Qin Liu; Joseph M Salvino; Donna L George; Ashani T Weeraratna; Qing Chen; Maureen E Murphy
Journal:  Cancer Res Commun       Date:  2021-10

Review 6.  Endothelial progenitor cells support tumour growth and metastatisation: implications for the resistance to anti-angiogenic therapy.

Authors:  Francesco Moccia; Estella Zuccolo; Valentina Poletto; Mariapia Cinelli; Elisa Bonetti; Germano Guerra; Vittorio Rosti
Journal:  Tumour Biol       Date:  2015-08-02

Review 7.  E Proteins and ID Proteins: Helix-Loop-Helix Partners in Development and Disease.

Authors:  Lan-Hsin Wang; Nicholas E Baker
Journal:  Dev Cell       Date:  2015-11-09       Impact factor: 12.270

8.  Cannabidiol Treatment Results in a Common Gene Expression Response Across Aggressive Cancer Cells from Various Origins.

Authors:  Pierre-Yves Desprez; Ryuichi Murase; Chandani Limbad; Rinette W L Woo; Isabel Adrados; Klemens Weitenthaler; Liliana Soroceanu; Nathan Salomonis; Sean D McAllister
Journal:  Cannabis Cannabinoid Res       Date:  2021-04-15

9.  Interplay between transforming growth factor-β and Nur77 in dual regulations of inhibitor of differentiation 1 for colonic tumorigenesis.

Authors:  Boning Niu; Jie Liu; Ben Lv; Jiacheng Lin; Xin Li; Chunxiao Wu; Xiaohua Jiang; Zhiping Zeng; Xiao-Kun Zhang; Hu Zhou
Journal:  Nat Commun       Date:  2021-05-14       Impact factor: 14.919

10.  Specific and Aspecific Molecular Checkpoints as Potential Targets for Dismantling Tumor Hierarchy and Preventing Relapse and Metastasis Through Shielded Cytolytic Treatments.

Authors:  Giovanni Manzo
Journal:  Front Cell Dev Biol       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.